Kimberly Eyer

Rheumatoid arthritis gut microbiome dysbiosis is marked by Collinsella expansion and Faecalibacterium loss, disrupting gut barrier function and promoting inflammation. These findings reveal potential diagnostic biomarkers and mechanistic pathways for microbiome-targeted interventions.

This study identifies oral microbiome biomarkers for arthritis screening, distinguishing RA from OA using salivary microbial profiles. It highlights Prevotella and Veillonella in RA and Rothia and Streptococcus in OA, supporting microbiome-based diagnostics.

Subgingival microbiome in rheumatoid arthritis reveals microbial community shifts driven by disease activity, smoking, and treatment. Prednisolone use correlates with healthier profiles, while smoking promotes dysbiosis, highlighting microbial biomarkers for RA management.

Subgingival microbiota in rheumatoid arthritis patients shows citrulline-producing and pro-inflammatory species enrichment despite periodontal health. These findings highlight Cryptobacterium curtum and networked anaerobes as potential contributors to RA pathogenesis and offer insight into early microbial biomarkers for immune-mediated disease.

This study reveals that gut microbiota dysbiosis in immune-mediated inflammatory diseases includes shared enrichment of pro-inflammatory taxa like Streptococcus and Eggerthella, alongside depletion of beneficial genera such as Roseburia. These patterns support a common microbial signature across IMIDs and highlight potential targets for diagnosis and therapeutic intervention.

This study reveals oral microbiota dysbiosis in rheumatoid arthritis, with distinct shifts in high-risk individuals before clinical symptoms. Prevotella_6 and Rothia were enriched, while Neisseria oralis was depleted, suggesting early microbial signatures and potential targets for diagnostic and preventive strategies in rheumatoid arthritis.

This review highlights how oral microbiota in rheumatoid arthritis patients shows pathogenic enrichment, increased cytokines, and worsened periodontal outcomes. These dysbiotic patterns, involving taxa like Prevotella and Parvimonas, suggest diagnostic and therapeutic implications, reinforcing the need to monitor oral health in RA.

This study explores the gut microbiome in early rheumatoid arthritis, revealing Prevotella enrichment and Collinsella depletion. These microbial shifts, seen before full disease onset, highlight the gut microbiome in early rheumatoid arthritis as a potential therapeutic target and biomarker for disease progression.

This study on intestinal microbiota in rheumatoid arthritis spouses reveals shared dysbiosis, with enrichment of Streptococcus and Blautia and depletion of Roseburia. These shifts implicate environment-driven microbial patterns in RA pathogenesis and highlight potential microbiome-based interventions for at-risk populations.

This study on the subgingival microbiome in rheumatoid arthritis and periodontitis identified Treponema enrichment in RA. Despite similar microbial richness across groups, specific dysbiotic shifts suggest that oral bacteria, particularly Treponema and Porphyromonas, may bridge periodontal and systemic inflammation in RA pathogenesis.

This study used gut microbiome metagenomics in rheumatoid arthritis to identify Prevotella enrichment and redox gene loss in RA. Findings reveal microbiome-host genomic interactions and metabolic shifts that define RA pathogenesis, offering population-specific microbial signatures and potential therapeutic targets based on microbial function and immunogenetic alignment.

This study links T2R38 genotype to oral microbiota composition in rheumatoid arthritis, revealing microbial shifts modulated by taste receptor polymorphisms. Findings suggest buccal dysbiosis in RA is partially shaped by host genetics, offering new insight into mucosal immunity and potential biomarkers for disease risk and microbial-targeted therapy.

This study found that oral microbiota in early rheumatoid arthritis displays distinct bacterial enrichments and metabolic shifts. Key taxa, including Filifactor alocis and Porphyromonas endodontalis, were elevated in RA regardless of periodontal status, highlighting their potential as biomarkers and microbial contributors to RA pathogenesis.

This study links the subgingival microbiome in rheumatoid arthritis to elevated ACPAs via enrichment of A. butyrica, P. simiae, and P. stomatis. These bacteria contribute to citrullination and may be key microbial biomarkers or MBTI targets in RA-associated periodontitis.

This study reveals that intrauterine microbial colonization is prevalent in women with endometriosis, particularly with Streptococcaceae, Staphylococcaceae, and Enterobacteriaceae. Findings suggest that GnRHa treatment exacerbates microbial colonization, indicating a possible role for targeted antimicrobial therapies in managing endometriosis-associated inflammation.

This study found that endometriosis does not induce significant changes in the fecal bacteriota composition during the acute phase of lesion formation. Findings suggest that gut microbial shifts in endometriosis may emerge only during chronic disease stages, highlighting the need for targeted microbiome interventions over prolonged periods.

This study shows that antibiotic therapy with metronidazole reduces endometriotic lesion growth and inflammation in mice by targeting the gut microbiota, particularly Bacteroidetes. Findings suggest that microbiota-targeted treatments may offer new therapeutic avenues for endometriosis management.

This study reveals distinct microbiome shifts in the vaginal, cervical, and gut microbiota of women with stage 3/4 endometriosis. The absence of Atopobium and elevated Gardnerella in reproductive sites suggest immune dysregulation, while Escherichia/Shigella dominance in stool samples correlates with bowel involvement, highlighting potential diagnostic biomarkers.

This study identifies microbiome shifts in the lower genital tract of Chinese women with endometriosis, marked by Atopobium enrichment and changes in ribosome biogenesis and immune modulation. Findings suggest potential non-invasive biomarkers and therapeutic targets for endometriosis and adenomyosis.

This study identifies gut microbiota and metabolomic shifts in endometriosis, with altered bile acid biosynthesis and ALA metabolism. Elevated CDCA and UDCA levels, coupled with microbial changes, suggest potential biomarkers and therapeutic targets for managing inflammation in endometriosis.

This study reveals a distinct microbiome profile in deep endometriosis, with unique bacterial communities in lesion sites, suggesting a role in inflammation and disease progression. Potentially pathogenic genera like Pseudomonas and Alishewanella were abundant, highlighting their possible involvement in endometriotic lesion maintenance and inflammatory responses.

This study identifies the vaginal microbiome as a predictor of endometriosis severity, highlighting microbial shifts that correlate with rASRM staging. Anaerococcus emerged as a key biomarker for advanced disease stages, while CST IV dominance during menstruation suggests inflammatory shifts. Findings support the potential of non-invasive microbiome-based diagnosis for endometriosis.

This study identifies disrupted brain-gut-microbiome interactions in IBS patients, revealing altered brain network dynamics and microbial shifts linked to symptom severity and cognitive dysfunction. These findings highlight the potential for targeted therapies addressing both brain connectivity and gut microbiota to improve IBS management.

This study reveals that diarrhea-predominant IBS (D-IBS) is linked to reduced microbial diversity and niche-specific dysbiosis in the gut.